97 related articles for article (PubMed ID: 113095)
1. Phase II evaluation of hexamethylmelamine in advanced breast cancer: a Southwest Oncology Group study.
Fabian CJ; Rasmussen S; Stephens R; Haut A; Smith F; Balcerzak S; Tranum B
Cancer Treat Rep; 1979 Aug; 63(8):1359-61. PubMed ID: 113095
[TBL] [Abstract][Full Text] [Related]
2. Phae II study of hexamethylmelamine in women with advanced breast cancer refractory to standard cytotoxic therapy.
Denefrio JM; Vogel CL
Cancer Treat Rep; 1978 Jan; 62(1):173-5. PubMed ID: 414835
[No Abstract] [Full Text] [Related]
3. Phase II study of hexamethylmelamine for disseminated prostatic carcinoma.
Drelichman A; Brownlee R; Al-Sarraf M
Cancer Clin Trials; 1981; 4(3):309-12. PubMed ID: 6793256
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of hexamethylmelamine, cis-diamminedichloroplatinum, and mitomycin-C in advanced breast cancer. A pilot study of the Southeastern Cancer Study Group.
Lawson D; Moore M; Smalley R
Cancer Clin Trials; 1980; 3(4):293-6. PubMed ID: 6775826
[TBL] [Abstract][Full Text] [Related]
5. Phase I--II study of hexamethylmelamine plus dibromodulcitol in refractory carcinoma of the breast.
Van Amburg AL; Presant CA; Vélez-García E; Klahr C
Cancer Treat Rep; 1979 Jan; 63(1):141-2. PubMed ID: 105806
[No Abstract] [Full Text] [Related]
6. Randomized phase II trial of hexamethylmelamine versus pentamethylmelamine in carcinoma of the bilharzial bladder.
Gad-el-Mawla N; Ziegler JL; Hamza R; Elserafi M; Khaled H
Cancer Treat Rep; 1984 May; 68(5):793-4. PubMed ID: 6426792
[No Abstract] [Full Text] [Related]
7. Contribution of prednisone to the effectiveness of hexamethylmelamine in multiple myeloma.
Oken MM; Lenhard RE; Tsiatis AA; Glick JH; Silverstein MN
Cancer Treat Rep; 1987 Sep; 71(9):807-11. PubMed ID: 3113729
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma.
Legha SS; Buzdar AU; Hortobagyi GN; DiStefano A; Wiseman CL; Yap HY; Blumenschein GR; Bodey GP
Cancer Treat Rep; 1979; 63(11-12):2053-6. PubMed ID: 118805
[TBL] [Abstract][Full Text] [Related]
9. Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer.
Chang YC; Falkson G; Tormey DC; Crowley J
Cancer Clin Trials; 1981; 4(4):377-80. PubMed ID: 6797746
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of pentamethylmelamine.
Ajani JA; Cabanillas FF; Bodey GP
Cancer Treat Rep; 1982 May; 66(5):1227-8. PubMed ID: 6805950
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of pentamethylmelamine: a clinical and pharmacologic study.
Ihde DC; Dutcher JS; Young RC; Cordes RS; Barlock AL; Hubbard SM; Jones RB; Boyd MR
Cancer Treat Rep; 1981; 65(9-10):755-62. PubMed ID: 6791819
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of hexamethylmelamine in refractory Hodgkin's disease, other lymphomas, and chronic lymphocytic leukemia.
Omura GA; Broun GO; Papps J; Birch R
Cancer Treat Rep; 1981; 65(11-12):1027-9. PubMed ID: 6794907
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
Bonomi PD; Mladineo J; Morrin B; Wilbanks G; Slayton RE
Cancer Treat Rep; 1979 Jan; 63(1):137-8. PubMed ID: 105805
[No Abstract] [Full Text] [Related]
14. [Effectiveness of ftorafur and hexamethylmelamine in advanced breast cancer].
Lichinitser MR; Perevodchikova NI; Garin AM; Asserkritova IV; Vaarik GKh
Vopr Onkol; 1978; 24(8):60-5. PubMed ID: 99870
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
Kardinal CG; Luce JK
Cancer Treat Rep; 1977 Dec; 61(9):1691-3. PubMed ID: 413624
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).
Rothenberg ML; Liu PY; Wilczynski S; Hannigan EV; Weiner SA; Weiss GR; Hunter VJ; Chapman JA; Tiersten A; Kohler PC; Alberts DS
Gynecol Oncol; 2001 Aug; 82(2):317-22. PubMed ID: 11531286
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study.
Gagliano RG; Stephens RL; Costanzi JJ; Oishi N; Stuckey WJ; Grozea PN; Frank J; Crawford ED
Cancer Treat Rep; 1984; 68(7-8):1025-6. PubMed ID: 6430559
[No Abstract] [Full Text] [Related]
18. Hexamethylmelamine in advanced head and neck cancer. A phase II study.
Gad-El-Mawla N; Macdonald JS; Khaled H
Am J Clin Oncol; 1984 Jun; 7(3):205-8. PubMed ID: 6428214
[TBL] [Abstract][Full Text] [Related]
19. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
Markman M; Blessing JA; Moore D; Ball H; Lentz SS
Gynecol Oncol; 1998 Jun; 69(3):226-9. PubMed ID: 9648592
[TBL] [Abstract][Full Text] [Related]
20. Hexamethylmelamine chemotherapy for disseminated endometrial cancer.
Seski JC; Edwards CL; Copeland LJ; Gershenson DM
Obstet Gynecol; 1981 Sep; 58(3):361-3. PubMed ID: 6791063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
